Iterion Therapeutics is a clinical-stage biotechnology company that focuses on developing innovative therapeutics for cancer. Their mission is to bring novel cancer treatments to patients who need them the most. Their lead drug, tegavivint, is a small molecule inhibitor of TBL1, a target in the downstream canonical Wnt-signaling pathway.

Tegavivint has shown promising safety, pharmacodynamic, and clinical activity in a Phase 1 Proof of Concept study for progressive desmoid tumors. Currently, Iterion is working on advancing a clinical program for hepatocellular carcinoma, which has significant unmet clinical needs. Additionally, they have investigator-sponsored studies in acute myeloid leukemia, non-small cell lung cancer, pediatric tumors, and lymphomas.

With a seasoned executive team experienced in advancing therapeutics from development to commercialization, Iterion Therapeutics aims to make significant contributions to the field of cancer treatment